- Business Wire•2 months ago
Professor Rudolph Tanzi, Founding Scientist and Chief Scientific Advisor for Prana Biotechnology, presented results obtained from testing PBT2, Prana’s lead candidate for Huntington and Alzheimer’s diseases, at the Alzheimer’s Association International Conference in Toronto, Canada on July 26, 2016.
- Insider Monkey•3 months ago
The US stock market is mixed, but relatively flat on Wednesday, following Federal Reserve Chairwoman Janet Yellen’s dovish message on interest rates, and ahead of tomorrow’s Brexit vote, which now seems like it will resolve toward a “Stay”. Among individual stocks, Prana Biotechnology Limited (ADR) (NASDAQ:PRAN), Michael Kors Holdings Ltd (NYSE:KORS), Advanced Micro Devices, Inc. […]
- Business Wire•5 months agoPrana Regains Compliance with NASDAQ Continued Listing Requirements Continues to Work Towards FDA Submission
Prana Biotechnology Ltd today announced that it has received a notice dated April 8th 2016 from the Listing Qualifications Department of NASDAQ Stock Market Inc.
Prana Biotechnology Limited (PBT.AX)
ASX - ASX Delayed Price. Currency in AUD
|Day's Range||0.10 - 0.11|
|52wk Range||0.06 - 0.15|
|1y Target Est||N/A|
|P/E Ratio (ttm)||-7.50|
|Avg Vol (3m)||174,666|
|Dividend & Yield||N/A (N/A)|